Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Journal of Sleep ResearchOpen Access

Risks Associated With Benzodiazepine Long‐Term Use in Chronic Insomnia: A Systematic Review and (Network) Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDieter RiemannCBChiara BaglioniCNChristoph Nissen

Discussion

Loading...

Member takes

Overview

Systematic review evaluates negative impacts of long-term benzodiazepine use in adults with insomnia, indicating need for alternative treatments.

Key Points

  • This review investigates the risks associated with prolonged benzodiazepine use in adults suffering from chronic insomnia.
  • Systematic literature review of 27 studies published from 1987 to 2023.
  • Focus on adults with insomnia lasting at least 3 months.
  • Meta-analysis conducted on the severity of insomnia, sleep quality, incidence of falls, depression, and anxiety.
  • Benzodiazepine users experienced more severe insomnia than healthy sleepers, but less severe than non-medicated individuals.
  • The risk of falls was similar between benzodiazepine users and non-users.
  • Users exhibited significantly higher levels of depression and anxiety compared to healthy sleepers.

Cite This Study

Riemann et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf688faef96ed7f058421https://doi.org/10.1111/jsr.70352
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prospective study of insomnia and incident asthma in adults: the HUNT study2017 · 33 citations
  2. 2The association between length of benzodiazepine use and sleep quality in older population2010 · 37 citations
  3. 3Is Long-Term Benzodiazepine Use a Risk Factor for Cognitive Decline? Results of a Systematic Review2020 · 37 citations
  4. 4The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness2016 · 131 citations
  5. 5Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia2023 · 15 citations